Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.955 USD | -1.76% | -6.46% | -37.54% |
03-28 | Arcadia Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-28 | Transcript : Arcadia Biosciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024 |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Ratings chart - Surperformance
Sector: Agricultural Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-37.54% | 2.66M | - | ||
+19.30% | 39.84B | C | ||
-.--% | 11.22B | - | B+ | |
-1.90% | 7.72B | A | ||
+2.38% | 6.54B | B- | ||
-4.29% | 5.97B | B+ | ||
-4.27% | 5.7B | B | ||
-11.80% | 5.52B | - | C- | |
+29.81% | 5.13B | B- | ||
-15.99% | 4.44B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- RKDA Stock
- Ratings Arcadia Biosciences, Inc.